PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fedratinib→

Fedratinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
936091-26-8
Molecular formula
C27H36N6O3S
Molecular weight
524.7 g/mol
Drug class
Janus kinase 2 (JAK2) inhibitortargeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits JAK2, including wild-type and mutationally activated forms, and has activity against FLT3. This reduces JAK-STAT signalling implicated in myeloproliferative neoplasm pathogenesis.
Indications / reported uses
  • Treatment of adults with intermediate-2 or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera or post-essential thrombocythaemia) under the current product label

Sources: US DailyMed — INREBIC (fedratinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fedratinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fedratinib Permitted Daily Exposure (PDE) report (the Fedratinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fedratinib Occupational Exposure Limit (OEL) report (the Fedratinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.